OSUR - OraSure Technologies, Inc.
OraSure Technologies, Inc. (NASDAQ: OSUR - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $3.71 and traded as high as $3.81. OraSure Technologies shares last traded at $3.71, with a volume of 355,981 shares. Analyst Ratings Changes Several equities analysts have weighed in
Establishment Labs (NASDAQ: ESTA - Get Free Report) and OraSure Technologies (NASDAQ: OSUR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations. Analyst Recommendations This is a summary of
Shares of OraSure Technologies, Inc. (NASDAQ: OSUR - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.68 and traded as high as $4.13. OraSure Technologies shares last traded at $3.77, with a volume of 534,071 shares trading hands. Analyst Ratings Changes OSUR has
Profusa (NASDAQ: PFSA - Get Free Report) and OraSure Technologies (NASDAQ: OSUR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk. Risk and Volatility Profusa has a beta of
OraSure Technologies, Inc. (OSUR) Q2 2026 Earnings Call Transcript
OraSure Technologies NASDAQ: OSUR reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth in sample-management products supported results.
BETHLEHEM, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2026.
BETHLEHEM, Pa. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2026. "Our Q2 results demonstrate continued progress in our return-to-growth trajectory, with revenue of $30.
BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5 p.m. Eastern Time on that day.
The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients. The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients.
BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche's tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems.
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.
BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026.
Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D.
OraSure Technologies, Inc. (NASDAQ: OSUR - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $2.77 and traded as high as $3.08. OraSure Technologies shares last traded at $3.06, with a volume of 304,439 shares traded. Wall Street Analyst Weigh In
Shares of OraSure Technologies, Inc. (NASDAQ: OSUR - Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.78 and traded as high as $2.99. OraSure Technologies shares last traded at $2.92, with a volume of 402,952 shares. Analyst Ratings Changes Separately, Weiss Ratings
Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commitment to driving value and acting in the best interests of all shareholders through disciplined execution and rigorous oversight.
LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the “Board”) outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. In the letter, Altai calls on the OraSure.
Activist investor Altai Capital Management called on OraSure Technologies to explore a sale, saying the medical device maker could fetch double its current share price, according to a letter seen by Reuters.